Menu
Search
Home > Courses > New DAAs and New DDIs: How Drug-Drug Interactions Continue To Vex HCV Treatment

New DAAs and New DDIs: How Drug-Drug Interactions Continue To Vex HCV Treatment

New DAAs and New DDIs: How Drug-Drug Interactions Continue To Vex HCV Treatment
Sorry, this learning module is not available for mobile devices.
COPYRIGHT: Videos of live meetings of PRN in NYC are owned and published by Physicians' Research Network, Inc. Copyright © 2016. All rights reserved.
COLLABORATION STATEMENT: The AIDS Institute is proud of the ongoing collaboration between the Clinical Education Initiative (CEI) and Physicians Research Network (PRN). Founded in 1990, PRN has a well-established reputation for spotlighting the work of the most innovative and influential leaders in the HIV treatment, prevention and research fields through its monthly meetings in New York City. Since 2010, CEI has featured recordings of PRN's monthly events through the CEI website. The combined efforts of both educational institutions have enhanced the continuing educational resources available to New York State clinicians caring for people living with, or at risk for HIV.
Approval Date: 12/13/2016
Published Date: 3/20/2017
Presenter
  • Charles W. Flexner, MD
    Professor of Medicine
    John Hopkins University School of Medicine
Presenter Bio
Charles Flexner, MD
Charles W. Flexner, M.D., is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. He is also Professor of International Health at the Bloomberg School of Public Health. Dr. Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. He has published extensively on antiviral and antibiotic drug transport and metabolism, and metabolic drug interactions. His current research focuses on the discovery and development of new molecules and formulations for long-acting parenteral administration for treatment and prevention of HIV infection. He directs the Long Acting/Extended Release Antiretroviral Research Resource Program (LEAP; www.longactinghiv.org), which provides advice and support to an international audience including the World Health Organization (WHO) and Unitaid. He is Co-Director of the Johns Hopkins University Baltimore-Washington-India HIV Clinical Trials Unit (BWI CTU), and currently chairs the Antiretroviral Strategies committee of the AIDS Clinical Trials Group. Dr. Flexner is the Chief Scientific Officer of the Institute for Clinical and Translational Research at Johns Hopkins, and is a member of the editorial board of 12 scientific journals. He currently serves on the WHO Clinical Guidelines Development Group for Treatment and Prevention of HIV in Adults, Adolescents, and Children.
Continuing Education Credit (The CE accreditation for this course has expired - this section is only for your information)

This CME activity was approved for AMA PRA Category 1 Credit™ on December 13, 2016 and will terminate December 12, 2019.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity. 

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. Charles Flexner (Presenter) had no relevant financial relationships to disclose.  Dr. Flexner submitted his slides in advance for adequate peer reiew, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.

Financial Support

This meeting of the Physicians' Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.

Details:

  • This online video and post-activity evaluation are one hour in length. 
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules